In Vivo Effects of a Ginkgo Biloba Extract on Platelet Activating Factor Metabolism in Two Asymptomatic Hiv-Infected Patients

• Published in: European journal of inflammation Vol. 9; no. 2; pp. 107 - 116
• Main Authors: Tsoupras, A.B., Chini, M., Tsogas, N., Mangafas, N., Demopoulos, C.A., Lazanas, M.C.
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.05.2011; SAGE PUBLICATIONS, INC
• Subjects: Antiretroviral drugs; Antiviral agents; Biosynthesis; Blood cells; CD4 antigen; Enzymes; Ginkgo biloba; highly active antiretroviral therapy; HIV; Human immunodeficiency virus; Infection; Infections; Leukocytes; Metabolism; Patients; Platelet-activating factor; Platelets; Transcription factors; ginkgolides; HIV-infection; PAF-metabolism; naïve patients; Ginkgo biloba extract; platelet activating factor (PAF)
• ISSN: 2058-7392; 1721-727X; 2058-7392
• DOI: 10.1177/1721727X1100900204

Ginkgo biloba products seem to protect from several pathological conditions, including HIV manifestations, where Platelet Activating Factor (PAF) is implicated. In the present study, we examined for the first time the in vivo effects of a standardized formulation of Ginkgo biloba extract (150 mg daily, per os) on PAF metabolism in blood cells and plasma of two male, asymptomatic HIV-infected patients, not receiving antiretroviral treatment, during a 9-month period. These patients differed at baseline in terms of duration of HIV infection, viral load levels, CD4 cell counts and Highly Active Antiretroviral Therapy (HAART) experience. In the first patient with early HIV infection, after an initial transient increase, a return of both plasma viral load and PAF biosynthetic enzyme activities in leukocytes to their baseline levels was observed during Ginkgo biloba use. As a result PAF degradation also remained low in this patient. The second patient with late but not advanced HIV infection, had higher levels of viral load and a lower CD4 cell count at baseline. The use of 150 mg of a Ginkgo biloba extract was probably insufficient to induce PAF degradation and/or to suppress the induction of PAF biosynthesis observed. At the same time, the initial high levels of viral load were further increased and CD4 cell counts were finally decreased during the study. The observed differences in PAF metabolism during Ginkgo use seem to be related to the initial heterogeneity of these patients. It appears that in some HIV-infected patients inhibition of the PAF/PAF-receptor system, along with a decrease/down-regulation of PAF-biosynthesis, illustrates a new potential role for Ginkgo biloba compounds in the treatment of HIV infection and its manifestations. However, more tests on a larger number of patients are needed in order to support these preliminary observations.